SCHEMBL531620

SCHEMBL531620

O=Cc1ccc2c(c1)NC(=O)C(F)O2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PARP1 P09874 2/20 0.36
USP2 O75604 1/20 0.36
GAA P10253 1/20 0.36
PTGS2 P35354 1/20 0.35
NR3C2 P08235 2/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
KDM4E B2RXH2 2/20 0.35
TSHR P16473 1/20 0.34
BRD4 O60885 1/20 0.33
CREBBP Q92793 1/20 0.33
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.33
CYP2A6 P11509 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAPK1 P28482 1/20 0.33
PDE3B Q13370 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5342897 0.81 PARP1 (0.57) ALDH1A1HSD17B10TDP1PARP1USP2
SCHEMBL532347 0.81 PARP1 (0.57) ALDH1A1HSD17B10TDP1PARP1USP2
SCHEMBL5188341 0.81 PARP1 (0.57) ALDH1A1HSD17B10TDP1PARP1USP2
SCHEMBL532921 0.78 USP2 (0.48) HSD17B10PARP1USP2GAAMEN1
SCHEMBL2288001 0.77 CA2 (0.50) ALDH1A1HSD17B10TDP1PARP1USP2
SCHEMBL2163564 0.76 L3MBTL1 (0.51) HSD17B10USP2GAAMEN1KMT2A
SCHEMBL7155529 0.73 PARP1 (0.62) ALDH1A1HSD17B10PARP1USP2GAA
SCHEMBL8117465 0.73 L3MBTL1 (0.48) HSD17B10PARP1USP2GAAMEN1
SCHEMBL2165889 0.72 L3MBTL1 (0.47) HSD17B10USP2GAAMEN1KMT2A
SCHEMBL15651034 0.70 ALDH1A1 (0.39) ALDH1A1HSD17B10TDP1PTGS2NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8669249-B2 Poly (ADP-ribose) polymerase (PARP) inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-11 US disclosed
US-8669249-B2 Poly (ADP-ribose) polymerase (PARP) inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-11 US disclosed
US-8669249-B2 Poly (ADP-ribose) polymerase (PARP) inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-11 US disclosed
US-20120094992-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
US-20120094992-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
US-20120094992-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
EP-2415767-A1 Poly (ADP-ribose) Polymerase (PARP) Inhibitors Takeda Pharmaceutical Company Limited (JP) 2012-02-08 EP disclosed
EP-2415767-A1 Poly (ADP-ribose) Polymerase (PARP) Inhibitors Takeda Pharmaceutical Company Limited (JP) 2012-02-08 EP disclosed
WO-2010111626-A2 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094992-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS PARP1, PARP2, PARP3 ALDH1A1 445/4885HSD17B10 1897/4885TDP1 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.